Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Link to XBRL Interactive Data 30 June 2018

September 3, 2018August 16, 2022 Kerry Rowe

https://www.sec.gov/cgi-bin/viewer?action=view&cik=1131343&accession_number=0001144204-18-047425&xbrl_type=v

2018

Post navigation

PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders

Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA

Related Posts

PBT434 poster presented at the 6th International Multiple System Atrophy Conference

March 6, 2018August 16, 2022

XBRL 30 June 2021 filed with the SEC

September 3, 2021August 16, 2022

Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial

July 29, 2019August 16, 2022

Recent Posts

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
XBRL 30 June 2022 filed with the SEC
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Appendix 4C – Q4 FY22 Quarterly Cash Flow Report
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065